Norvir (ritonavir)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Immunology/Infectious Diseases
General Information
Norvir soft-gelatin capsules (new formulation) have been
approved for the treatment of HIV infection. Norvir is a protease
inhibitor indicated in combination with other antiretroviral
medications for the treatment of HIV infection. The soft-gel
capsules required refrigerated storage until dispensed to patients.
Norvir is approved for twice-daily use and should be taken with
food, if possible.
Clinical Results
Taken in combination with other antiretroviral medications for
the treatment of HIV infection, this indication for Norvir is based
on the results from a study in patients with advanced HIV disease
that showed a reduction in both mortality and AIDS-defining
clinical events. Norvir has also been approved by the FDA for use
in children between the ages of 2 and 16 based on safety and
pharmacokinetic data.
Side Effects
Common adverse reactions include fatigue, vomiting, diarrhea,
loss of appetite, abdominal pain, taste disturbance, tingling
sensation or numbness in the hands, feet, or around the lips,
headache and dizziness.
